Acute hepatocellular and cholestatic injury in a patient taking celecoxib.
A case of acute hepatocellular and cholestatic liver injury that may have been associated with the use of celecoxib is described. This case was reported to US Food and Drug Administration and the manufacturer of celecoxib.
Nachimuthu
S
S
Department of Internal Medicine, Lutheran Medical Center, State University of New York Health Science Center, Brooklyn, NY 11220, USA. nsen1@hotmail.com
Volfinzon
L
L
Gopal
L
L
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000068579:Celecoxib; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000503:physiopathology; D002779:Cholestasis / Q000139:chemically induced* / Q000503:physiopathology; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D010003:Osteoarthritis / Q000188:drug therapy*; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib